PCM
PRTK

Penserra Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Penserra Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,110
Closed -$5K – 1608
2021
Q3 		$5K Buy
1,110
+40
+4% +$220 ﹤0.01% 1415
2021
Q2 		$7K Buy
1,070
+20
+2% +$162 ﹤0.01% 1303
2021
Q1 		$7K Hold
1,050
– – ﹤0.01% 1067
2020
Q4 		$6K Buy
+1,050
New +$6.18K ﹤0.01% 981

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penserra Capital Management's PRTK Position: Q4 2021 in Review

Penserra Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2021, closing a stake of 1,110 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in PRTK in Q4 2020 and held it in 4 quarters. The position peaked at $7K in Q2 2021. 103 funds tracked by Wall St. Rank hold PRTK as of Q4 2021.

  • Penserra Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,110 Paratek Pharmaceuticals, Inc. shares in Q4 2021, an estimated $5K.
  • Penserra Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $7K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.